Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa for moderate or severe traumatic brain injury
ACTRN12609000827235Phase 3Completed
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
- Start
- May 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in traumatic brain injury (TBI) (2 arms), sponsored by Australian and New Zealand Intensive Care Research Centre. Primary endpoint: Unfavourable neurological outcome or death at 6 months. Started May 2010; status: completed.
02
Drugs
epoetin alfa
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on ACTRN12609000827235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000827235.